TY  - GEN
AU  - Tagit,Oya
AU  - Tagit,Oya
TI  - Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside
SN  - books978-3-0365-4489-2
PY  - 2022///
CY  - Basel
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Technology: general issues
KW  - bicssc
KW  - History of engineering & technology
KW  - Materials science
KW  - poly(lactic-co-glycolic acid) (PLGA)
KW  - blood-brain barrier (BBB)
KW  - current Good Manufacturing Practice (cGMP)
KW  - Food and Drug Administration (FDA)
KW  - nanotechnology
KW  - PLGA nanoparticles
KW  - neurodegenerative diseases
KW  - drug delivery
KW  - central nervous system
KW  - neuroprotective drugs
KW  - fluorescent labeling
KW  - DiI
KW  - coumarin 6
KW  - rhodamine 123
KW  - Cy5.5
KW  - quantum yield
KW  - brightness
KW  - stability of fluorescent label
KW  - confocal microscopy
KW  - intracellular internalization
KW  - in vivo neuroimaging
KW  - double-emulsion method
KW  - dry powder inhalation
KW  - antigen release
KW  - porous PLGA particles
KW  - microfluidics
KW  - methotrexate
KW  - chitosan
KW  - PLA/PLGA
KW  - sustained release
KW  - micro-implant
KW  - animal model
KW  - minimally invasive
KW  - drug delivery system
KW  - nanoparticles
KW  - poly (lactic-co-glycolic acid) (PLGA)
KW  - microfluidic
KW  - pharmacokinetics (PK) and biodistribution
KW  - atorvastatin calcium
KW  - poly(lactide-co-glycolide)
KW  - polymeric nanoparticles
KW  - carrageenan induced inflammation
KW  - anti-inflammatory
KW  - radiolabeled nanoparticles
KW  - nuclear medicine
KW  - photothermal therapy
KW  - phthalocyanine
KW  - SKOVip-kat
KW  - Katushka
KW  - TurboFP635
KW  - JO-4
KW  - PLGA
KW  - orthotopic tumors
KW  - 3D culture
KW  - spheroids
KW  - poly(lactic-co-glycolic acid)
KW  - nanomedicine
KW  - scale-up manufacturing
KW  - clinical translation
KW  - inline sonication
KW  - tangential flow filtration
KW  - lyophilization
KW  - downstream processing
KW  - H. pylori
KW  - design of experiments
KW  - poly(lactic-co-glycolic) acid
KW  - size
KW  - cancer
KW  - chemoimmunotherapy
KW  - immunogenic cell death
KW  - immune checkpoint blockade
KW  - PNA5 glycopeptide
KW  - mas receptor
KW  - angiotensin
KW  - PLGA diblock copolymer
KW  - ester and acid-end capped
KW  - double emulsion solvent evaporation
KW  - biocompatible
KW  - biodegradable
KW  - cardiovascular
KW  - nanoparticle
KW  - solid-state characterization
KW  - in vitro
KW  - drug release kinetics modeling
KW  - PEGylation
KW  - amine
KW  - emulsion
KW  - polyvinyl alcohol (PVA)
KW  - Pluronic triblock copolymer
KW  - trehalose
KW  - sucrose
KW  - Indomethacin
KW  - solvents
KW  - stabilizers
KW  - morphology
KW  - particle-size
KW  - encapsulation
KW  - drug release
KW  - cytotoxicity
N1  - Open Access
N2  - Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations
UR  - https://mdpi.com/books/pdfview/book/5741
UR  - https://directory.doabooks.org/handle/20.500.12854/87543
ER  -